GLP Watchdog

altRX vs Hims

altRX has an open FDA warning letter dated June 8, 2026. Hims has an open FDA warning letter dated September 9, 2025. No price lines up like for like. They share brand-name semaglutide pen, but Hims' $199 covers the medication only, with a separate membership on top.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

altRX / Hims

Featured pick (affiliate partner)

altRX logo

altRX

8.8/10

Hims logo

Hims

6.7/10

FDA warning letters
Pharmacy
  • RedRock Pharmacy503A
  • Health Warehousetype not stated
  • Precision Medicinetype not stated
  • and 1 more
Lowest standing price
$89/moCompounded semaglutide injection
$149/moBrand-name semaglutide pill, medication only, membership extra
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit altRX
Visit Hims

altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Hims pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Hims 6.7). How we are paid

What the record shows

  1. 01

    altRX has an open FDA warning letter dated June 8, 2026. Hims has an open FDA warning letter dated September 9, 2025.

  2. 02

    altRX names four pharmacies. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like. They share brand-name semaglutide pen, but Hims' $199 covers the medication only, with a separate membership on top.

  4. 04

    Only altRX lists a price for compounded semaglutide injection and compounded tirzepatide injection. Only Hims lists a price for brand-name semaglutide pill and Foundayo (orforglipron) pill.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

altRX

Hims

Brand-name semaglutide pen

$1,149/mo

$13,788 a year

$199/mo

medication only, membership extra; not compared

Brand-name tirzepatide pen

$1,249/mo

$14,988 a year

$299/mo

medication only, membership extra; not compared

Compounded semaglutide injection

$89/mo

$1,068 a year

Not sold or not priced
Compounded tirzepatide injection

$149/mo

$1,788 a year

Not sold or not priced
Brand-name semaglutide pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Foundayo (orforglipron) pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Price includes
Medication, clinician visits, shipping
Medication
Billed separately
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; multi-month plans are prepaid and non-refundable
Monthly membership, auto-renews
Refunds
All payments are final and non-refundable, except a partial refund if you are medically disqualified
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. altRX: September 28, 2026. Hims: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for altRX

8.8/10
Featured pick (affiliate partner)
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Hims does not price
  • Price includes clinician visits
  • Open FDA warning letter, June 8, 2026
Visit altRX

The case for Hims

6.7/10
  • Sells brand-name semaglutide pill and Foundayo (orforglipron) pill, which altRX does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

Scores

altRX 8.8 · Hims 6.7 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
3.0

The score is the same formula for every seller. Payment does not enter it. Method

altRX vs Hims: questions

altRX has an open FDA warning letter dated June 8, 2026. Hims has an open FDA warning letter dated September 9, 2025. Letters are matched to a seller by company, domain and address, never by a similar name.
altRX names four pharmacies. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like. They share brand-name semaglutide pen, but Hims' $199 covers the medication only, with a separate membership on top. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
altRX states you can cancel at any time; refunds: all payments are final and non-refundable, except a partial refund if you are medically disqualified. Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed.
altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Hims pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Hims 6.7).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks